Trial site
Lawrence J. Green, MD, LLC
Rockville, Maryland 20850, United StatesNot linked to an institution yet
- 4running trials
- 9closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 22 trials
- Status
- Completed8 trials
- Active, not recruiting3 trials
- Recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Takeda3 trials
- Janssen Research & Development, LLC2 trials
- Pfizer2 trials
- Bristol-Myers Squibb1 trial
- Eli Lilly and Company1 trial
- and 4 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT06973291· Phase 3· Takeda· Source
Completed
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06588283· Phase 3· Eli Lilly and Company· Source
Terminated
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
NCT06493578· Phase 2· Vyne Therapeutics Inc.· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Takeda· Source
Completed
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT06144424· Phase 2· Escient Pharmaceuticals, Inc· Source
Completed
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189· Phase 3· Janssen Research & Development, LLC· Source
Completed
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526· Phase 3· Pfizer· Source
Completed
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
NCT05272150· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
NCT04921969· Phase 3· Incyte Corporation· Source
Report an error